NasdaqGS:EXELBiotechs
Will Exelixis' (EXEL) New R&D Leadership Shape Its Competitive Edge in Oncology Innovation?
Exelixis recently appointed Dana T. Aftab, Ph.D., as Executive Vice President of Research and Development, placing him in charge of all drug discovery, translational research, product development, and medical affairs activities; this follows the departure of Amy Peterson, M.D., from her executive and chief medical officer roles.
Dr. Aftab's extensive history with Exelixis and his contribution to the development of CABOMETYX may signal a renewed focus on pipeline leadership as the company...